Oncology News

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.

The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the agents’ manufacturer.

Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.

Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.

CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.

Foreign-born patients with hepatocellular carcinoma had higher survival rates than those born in the United States, according to data published in JNCI: Journal of the National Cancer Institute.

Overweight and obese BMI during adulthood appeared associated with increased risk for colorectal cancer and noncolorectal gastrointestinal cancers, according to study results published in JAMA Network Open.

Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.

Physically active patients with nonalcoholic fatty liver disease were more likely to achieve at least a 30% reduction in MRI-measured liver fat, according to research in The American Journal of Gastroenterology.

Single-fraction radiation therapy reduced hepatic pain among most patients with end-stage hepatocellular carcinoma or liver metastases, according to randomized phase 3 study results presented at ASCO Gastrointestinal Cancers Symposium.